REGISTER RECORD · clinicaltrials.gov
NCT03739814
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | RECRUITING: currently recruiting participants |
|---|---|
| Register last updated | 2026-08-21 |
| Retrieved by this site | 2026-08-31 |
| Source | https://clinicaltrials.gov/study/NCT03739814 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.